Novel response to neoadjuvant anti-PD1 therapy for a patient with retrocaval melanotic schwannoma

This report demonstrates a significant improvement in symptomatology and tumor stability with neoadjuvant anti-PD1 therapy for a retrocaval melanotic schwannoma initially masquerading as malignant melanoma. This report demonstrates the potential benefit of a novel therapeutic option for patients with melanotic schwannoma.
Source: Melanoma Research - Category: Cancer & Oncology Tags: Short Communications Source Type: research